News

Catalent to Acquire Metrics Contract Services for $475 Million

August 10, 2022

Catalent will acquire Metrics Contract Services for $475 million to expand high-potent capabilities and oral development and manufacturing capacity.

FDA Approves Coherus’ Interchangeable Biosimilar for Lucentis

August 10, 2022

FDA has approved Coherus’ Cimerli (ranibizumab-eqrn) as an interchangeable biosimilar for all five indications of Lucentis.

Sanofi and Innovent Enter Oncology Collaboration

August 10, 2022

Sanofi and Innovent have entered into a strategic collaboration to accelerate development of oncology medicines and expand their presence in China.

Senate Advances Drug Price Negotiations

August 10, 2022

Democrats approve curbs for Medicare plans, but not for commercial drug coverage.

Amgen Will Acquire Chemocentryx in $4 Billion Deal

August 09, 2022

Amgen’s acquisition of Chemocentryx includes the autoimmune disease drug Tavneos (avacopan).

EC Approves Additional Indication for Lynparza as Adjuvant Treatment in Breast Cancer

August 09, 2022

The European Commission has approved AstraZeneca and Merck’s Lynparza (olaparib) as an adjuvant treatment for BRCA-mutated HER2-negative high-risk early breast cancer.

AES Clean Technology Launches OMNI Electric Utility Raceway

August 05, 2022

The OMNI Electric Utility Raceway power and data management system is designed to reduce risk and accelerate cleanroom delivery.

La Jolla Institute for Immunology Acquires Carterra LSA Platform

August 05, 2022

La Jolla’s acquisition of Carterra’s LSA Platform is designed to advance their immunological and infectious disease research.

Synthego Aims to Accelerate Drug Discovery with New Engineered Cell Libraries

August 04, 2022

Synthego has launched new engineered cell libraries to validate targets for quicker drug discovery timelines.

Top Priority for Califf Is Combatting Health Misinformation

August 04, 2022

Better clinical data are needed, as well as strategies for tackling opioid abuse, tobacco use, and food safety.